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Background
The endocannabinoid system (ECS) is comprised of
cannabinoid receptors, lipid messengers called endocanna-
binoids, and the enzymes that metabolize them. It modu-
lates numerous processes including the central nervous
and immune systems as well as cell signaling pathways
important in normal function and diseases such as cancer.
Many studies have demonstrated anti-tumour effects of
synthetic and endogenous cannabinoids in cancer, empha-
sizing the potential for ECS modulators as anti-cancer
therapies. We believe that ECS deregulation may contri-
bute to the malignant phenotype of lung cancer cells by
reducing anti-tumour endocannabinoid levels and conse-
quently increasing levels of arachidonic acid, which can
promote tumour growth. We sought to determine
whether the ECS is disrupted in clinical lung tumours and
whether disruption has prognostic implications.
Materials and methods
We hypothesize that recurrent downregulation of cannabi-
noid receptors (CNR1, CNR2) or upregulation of metabo-
lizing enzymes (FAAH, FAAH2, MGLL) occurs in lung
tumours to prevent the anti-tumor effects of endocannabi-
noids. We assessed the gene expression, copy number, and
DNA methylation status of these ECS components in two
independent lung cancer cohorts with genomic profiles for
patient matched lung adenocarcinoma and non-malignant
tissues (BC Cancer Agency (BCCA) and The Cancer
Genome Atlas (TCGA)). We also investigated associations
between ECS disruption and patient outcome.
Results
The ECS was recurrently disrupted in both lung adenocar-
cinoma cohorts; 78% and 82% of tumours in the BCCA
(n=83) and TCGA (n=57) cohorts, respectively, harboured
gene expression changes consistent with our hypothesis in
at least one of the five components assessed. Underexpres-
sion of CNR1 and overexpression of FAAHs were the
most prominent alterations observed, and were associated
with copy losses and gains, respectively. Frequent promo-
ter hypomethylation affecting CNRs and FAAH was also
observed but was only associated with concordant overex-
pression for FAAH. Survival analysis revealed ECS disrup-
tion, specifically CNR1 underexpression and/or FAAH
overexpression, was significantly associated with poor
survival (Mantel-Cox p-value = 0.0128) in the BCCA
cohort. A similar non-significant trend was observed in
the TCGA cohort (Mantel-Cox p-value = 0.0561).
Conclusions
Components of the ECS undergo frequent genetic changes
which may compromise the function of this system in lung
cancer cells. The recurrent nature of ECS disruption and
its association with poor prognosis suggests deregulation
is selected for in lung adenocarcinoma. We believe ECS
disruption status may predict sensitivity of lung cancer
cells to the anti-tumour effects of ECS targeting agents
and plan to investigate this in future work.
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